@article{open2660,
          volume = {12},
           month = {February},
          author = {Rajeev K Tyagi and Justin Jacobse and Jing Li and Margret M. Allaman and Kevin L. Otipoby and Erik R. Sampson and K T Wilson and Jeremy A. Goettel},
            note = {Open Access},
           title = {HLA-Restriction of Human Treg Cells Is Not Required for Therapeutic Efficacy of Low-Dose IL-2 in Humanized Mice},
       publisher = {Frontiers},
         journal = {Frontiers in immunology},
            year = {2021},
        keywords = { IBD; IL-2; Tregs; colitis; humanized.},
             url = {http://crdd.osdd.net/open/2660/},
        abstract = {Regulatory T (T-reg) cells are essential to maintain immune homeostasis in the intestine and T-reg cell dysfunction is associated with several inflammatory and autoimmune disorders including inflammatory bowel disease (IBD). Efforts using low-dose (LD) interleukin-2 (IL-2) to expand autologous T-reg cells show therapeutic efficacy for several inflammatory conditions. Whether LD IL-2 is an effective strategy for treating patients with IBD is unknown. Recently, we demonstrated that LD IL-2 was protective against experimental colitis in immune humanized mice in which human CD4(+) T cells were restricted to human leukocyte antigen (HLA). Whether HLA restriction is required for human T-reg cells to ameliorate colitis following LD IL-2 therapy has not been demonstrated. Here, we show that treatment with LD IL-2 reduced 2,4,6-trinitrobenzensulfonic acid (TNBS) colitis severity in NOD.Prkdc(scid)Il2rg(-/-) (NSG) mice reconstituted with human CD34(+) hematopoietic stem cells. These data demonstrate the utility of standard immune humanized NSG mice as a pre-clinical model system to evaluate therapeutics targeting human T-reg cells to treat IBD.}
}